WaveMan
WaveMan · Company
VRTX · Vertex Pharmaceuticals Inc / Ma
> Search tickers & screens ⌘K
LIVE
← All companies

VRTX Vertex Pharmaceuticals INC / MA (VRTX) Insider Trading, Ownership & Congress Trades

Pharma & Biotech · Pharmaceutical preparations · CIK 0000875320
Quote by TradingView
Form 144 · 1
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
0
13F, latest reported quarter

What the filings say about VRTX

Insiders, 180 days
-$11.0M net sold
6 sellers · 0% of sales under a 10b5-1 plan
Congress, 1 year
0 bought · 1 sold
Latest: sale, 2026-08-26
Planned sales (Form 144), 90 days
$662.5K
1 notice

Vertex Pharmaceuticals INC / MA insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

Over the last 180 days, VERTEX PHARMACEUTICALS INC / MA insiders sold a net $11.0M of stock across 602 Form 4 purchases and sales, with no insider buying. Source: SEC Form 4 filings, as of 2026-10-27.

Insider
Filed
Shares
Value
Since filing
McKechnie Duncan
EVP, Chief Commercial Officer
SELL
2026-07-07 SECtraded 2026-07-02
1,541
$799.8K
+3.8%
Context
  • 4 earlier Form 4 trades (code P or S) here by this insider (4 sales), the last on Mar 11, 2026.
  • The trade is 14.0% of the 11,001 shares held after it.
  • 3 other insiders sold within 30 days.
Insider activity: EVP, Chief Commercial Officer McKechnie Duncan sold about $799.8K of VRTX on Jul 2, 2026; 3 other insiders sold within 30 days.
Tatsis Ourania
EVP, Chief Reg. & Quality Off.
SELL
2026-07-07 SECtraded 2026-07-02
1,500
$787.5K
+3.8%
Context
  • 59 earlier Form 4 trades (code P or S) here by this insider (59 sales), the last on Feb 25, 2026.
  • The trade is 3.3% of the 45,321 shares held after it.
  • 3 other insiders sold within 30 days.
Insider activity: EVP, Chief Reg. & Quality Off. Tatsis Ourania sold about $787.5K of VRTX on Jul 2, 2026; 3 other insiders sold within 30 days.
Liu Joy
EVP and Chief Legal Officer
SELL
2026-07-06 SECtraded 2026-07-01
828
$416.2K
-0.9%
Context
  • 22 earlier Form 4 trades (code P or S) here by this insider (22 sales), the last on Jun 1, 2026.
  • The trade is 4.3% of the 19,131 shares held after it.
  • 3 other insiders sold within 30 days.
Insider activity: EVP and Chief Legal Officer Liu Joy sold about $416.2K of VRTX on Jul 1, 2026; 3 other insiders sold within 30 days.
Bozic Carmen
EVP and CMO
SELL
2026-06-30 SECtraded 2026-06-26
596
$287.6K
+3.9%
Context
  • 21 earlier Form 4 trades (code P or S) here by this insider (21 sales), the last on Jun 18, 2026.
  • The trade is 3.9% of the 15,337 shares held after it.
  • 3 other insiders sold within 30 days.
Insider activity: EVP and CMO Bozic Carmen sold about $287.6K of VRTX on Jun 26, 2026; 3 other insiders sold within 30 days.
Bozic Carmen
EVP and CMO
SELL
2026-06-23 SECtraded 2026-06-18
1,020
$471.4K
+8.9%
Context
  • 20 earlier Form 4 trades (code P or S) here by this insider (20 sales), the last on Jun 15, 2026.
  • The trade is 6.4% of the 15,933 shares held after it.
  • 3 other insiders sold within 30 days.
Insider activity: EVP and CMO Bozic Carmen sold about $471.4K of VRTX on Jun 18, 2026; 3 other insiders sold within 30 days.
602 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to see 597 more transactions and use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
net -$11.0M over 180 days
below 85% of Pharma & Biotech
Congress
no House purchase disclosed in the last 12 months
Funds
under five funds report holding it
Revenue
+8.9% year over year
more than 58% of Pharma & Biotech
Margin
32.9% net margin
more than 92% of Pharma & Biotech
Buybacks
$806.4M repurchased, FY to 2026-06-30
more than 92% of Pharma & Biotech
Short interest
1.8% of the float short (float per yahoo 2026-10-26) · 4.2 days to cover · settled 2026-09-30
below 67% of Pharma & Biotech
What changed in the last 30 days
Oct 27Insider selling stopped: no sales in 90 days after 14 in the prior 90
Why it matters
The absence is the signal: 14 sales in one 90-day window and none in the next is a change of behaviour, not a filing.

Watch VRTX

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
+21.4%12M
-4%+8%+19%+31%2025-102025-122026-022026-042026-062026-082026-10 2025-11-14 · LEIDEN JEFFREY M sold $14.2M2025-11-14 · LEIDEN JEFFREY M sold $9.4M2026-02-19 · Sachdev Amit sold $9.2M2025-11-13 · LEIDEN JEFFREY M sold $8.2M2026-02-27 · Kewalramani Reshma sold $7.7M2025-12-03 · LEIDEN JEFFREY M sold $7.1M2026-02-19 · Sachdev Amit sold $5.5M2026-02-19 · Sachdev Amit sold $4.8M2025-12-03 · LEIDEN JEFFREY M sold $4.7M2026-01-06 · WAGNER CHARLES F JR sold $4.4M2025-12-03 · LEIDEN JEFFREY M sold $3.5M2026-02-19 · Sachdev Amit sold $3.4M2025-12-03 · WAGNER CHARLES F JR sold $3.2M2025-12-03 · WAGNER CHARLES F JR sold $3.2M2026-05-12 · Bozic Carmen sold $3.1M2026-02-27 · Kewalramani Reshma sold $3.0M2025-12-03 · LEIDEN JEFFREY M sold $2.6M2025-12-03 · LEIDEN JEFFREY M sold $2.6M2026-01-07 · Tatsis Ourania sold $2.1M2025-12-03 · Tatsis Ourania sold $2.0M2026-02-19 · Sachdev Amit sold $2.0M2025-12-03 · LEIDEN JEFFREY M sold $2.0M2025-12-03 · LEIDEN JEFFREY M sold $1.9M2026-06-15 · Bozic Carmen sold $1.8M2026-02-27 · Kewalramani Reshma sold $1.7M2026-02-27 · Kewalramani Reshma sold $1.6M2026-02-27 · Kewalramani Reshma sold $1.3M2026-03-11 · McKechnie Duncan sold $1.3M2026-02-19 · Sachdev Amit sold $1.3M2026-02-27 · Kewalramani Reshma sold $1.2M2026-02-27 · Kewalramani Reshma sold $1.2M2026-02-25 · McKechnie Duncan sold $1.2M2026-02-17 · Biller Jonathan sold $1.2M2026-02-17 · Bunnage Mark E. sold $1.2M2026-02-25 · McKechnie Duncan sold $1.2M2026-03-04 · McKechnie Duncan sold $1.2M2026-03-13 · Bozic Carmen sold $1.1M2026-02-27 · Bozic Carmen sold $1.1M2025-12-03 · LEIDEN JEFFREY M sold $1.1M2025-11-17 · Atkinson Edward Morrow III sold $1.1M2026-03-27 · Bozic Carmen sold $1.1M2025-12-03 · LEIDEN JEFFREY M sold $1.0M2026-08-27 · Bruce I. Sachs filed to sell $662.5K2026-07-02 · McKechnie Duncan filed to sell $799.8K2026-07-02 · Tatsis Ourania filed to sell $787.5K2026-07-01 · Liu Joy filed to sell $416.2K2026-06-26 · Bozic Carmen filed to sell $287.6K2026-06-18 · Bozic Carmen filed to sell $471.4K
Insider sellForm 144 (planned sale)
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns VRTX: institutional holders (13F)

13F holdings, latest reported quarter
SEC 13F
No reported 13F holders

No fund above the reporting threshold listed this stock last quarter. That is a fact, not missing data.

Congress trades in VRTX

STOCK Act disclosures, US House only, filed up to 45 days after the trade
David J. Taylor
Sold 2026-08-26 · disclosed 10 days later
$1,001 - $15,000
David J. Taylor
Sold 2026-01-29 · disclosed 4 days later
$1,001 - $15,000
David J. Taylor
Bought 2025-08-07 · disclosed 26 days later
$1,001 - $15,000
Lisa McClain
Sold 2025-06-11 · disclosed 63 days later
$1,001 - $15,000
Lisa McClain
Sold 2025-06-10 · disclosed 64 days later
$1,001 - $15,000
All stocks members of Congress are buying · Every member's trades

Activist and 5% holders (13D/13G)

No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.

VRTX planned insider sales (Form 144)

Notice of intent to sell, filed before any sale
Bruce I. Sachs
Filed 2026-08-27
$662.5K
McKechnie Duncan
Filed 2026-07-02
$799.8K
Tatsis Ourania
Filed 2026-07-02
$787.5K
Liu Joy
Filed 2026-07-01
$416.2K
Bozic Carmen
Filed 2026-06-26
$287.6K
Executive pay vs shareholder return · Reshma Kewalramani
CEO pay, headline and as actually paid, against the company's return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2025
$21.1M
$38.2M
$7.7M
+92%
+25%
2024
$21.5M
$43.6M
$8.1M
+70%
-7%
2023
$20.6M
$44.2M
$7.4M
+72%
-6%
2022
$15.9M
$29.5M
$9.0M
+22%
-10%
2021
$15.2M
$18.3M
$7.2M
-7%
+0%
Tagged by the company under SEC Item 402(v). Returns are cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders have filed to sell, before selling.
The record shows a net $11.0M sold by insiders over 180 days, $662.5K in planned Form 144 sales. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
UTHRCPIXMRNAREGNLLYALNYMDGLCITRDNANUVLTWSTKYMR

VRTX financials

Revenue growth
+8.9%
XBRL, annual
Net margin
32.9%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$12.6B
four quarters, 2025-07-01 to 2026-06-30
Net margin, TTM
+35.0%
net income over revenue, 2025-07-01 to 2026-06-30
Free cash flow, TTM
$3.8B
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Debt to equity
n/a
no debt line filed
Cash flow to debt
n/a
no debt line filed
Return on equity
+23.5%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets
+17.1%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on invested capital
n/a
no debt line filed
Return on capital employed
+22.0%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
P/E, trailing
30.14x
close 2026-10-26 over four quarters of diluted EPS, 2025-07-01 to 2026-06-30
Enterprise value
n/a
no debt line filed
FCF yield
+2.9%
TTM free cash flow over market value at close 2026-10-26
PEG, trailing
1.34x
P/E over trailing EPS growth of 22%: four quarters to 2026-06-30 against the four to 2025-06-30
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2025-122024-122023-122022-12
Revenue$12.0B$11.0B$9.9B$8.9B
Operating income$4.2B-$232.9M$3.8B$4.3B
Net income$4.0B-$535.6M$3.6B$3.3B
EPS (diluted)15.32-2.0813.8912.82
Operating cash flow$3.6B-$492.6M$3.5B$4.1B
Cash$5.1B$4.6B$10.4B$10.5B
Buybacks$2.0B$1.2B$427.6M$0
SEC XBRL, fiscal years, as known on 2026-10-27

VRTX Stock Sonar score 5/7 axes

Find similar shapesCompare

VRTX ranks highest on profitability (92nd percentile) and growth (58th), and lowest on insider conviction (7th), among Pharma & Biotech peers.

ProfitGrowthInsidersInstitutionsRisk
Profitability
92
Inputs
  • Return on equity+23.5% · 90 pct, sector of 545
  • Return on assets+17.1% · 91 pct, sector of 691
  • Return on invested capitalno debt line filed
  • Return on capital employed+22.0% · 95 pct, sector of 576
Growth
58
Inputs
  • Revenue growth, YoY+8.9% · 58 pct, sector of 505
  • Backlog growth, YoYno backlog line filed, or no year-earlier backlog
Insider conviction
7
Inputs
  • Net Form 4 buying (codes P and S), 180d-$11.0M · 13 pct, sector of 428
  • Insider buyers, 180d0 · 0 pct, sector of 437
Institutional and government
10
Inputs
  • Funds adding, latest quarterfewer than five funds report holding it
  • Congress net buyers, 365d-1 · 10 pct, sector of 49
  • Federal contracts, 180dno federal contracts in 180 days
  • Lobbying spend, 4 quartersno lobbying filings in the last four quarters
Risk and compliance
39
Inputs
  • Short interest, % of float+1.8% · 75 pct, sector of 813
  • Recalls per $1B revenue, 3ynot measured for this sector, almost no peer has an event
  • EPA cases per $1B revenue, 5ynot measured for this sector, almost no peer has an event
  • New text in Risk Factors, latest 10-K+67.2% · 2 pct, sector of 511
2 not measured: Financial health, US patents
  • Financial health needs 1 of 2 inputs, 0 present: no debt line filed
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

5 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

VRTX filings, in plain words

Are Vertex Pharmaceuticals INC / MA insiders buying or selling VRTX?

In the 180 days to 2026-10-27, Vertex Pharmaceuticals INC / MA insiders were net sellers, a net $11.0M across purchases and sales reported on Form 4, by 6 sellers.

Have members of Congress traded VRTX?

Yes. In the year to 2026-10-27, 0 House members disclosed buying VRTX and 1 House member disclosed selling it; the latest on record is a sale by David J. Taylor dated 2026-08-26.

Are there planned insider sales of VRTX?

Yes. 1 Form 144 notice of planned insider sales was filed in the 90 days to 2026-10-27, covering $662.5K of stock; the latest, by Bruce I. Sachs, was filed 2026-08-27.

Read the full summary

In the 180 days to 2026-10-27, Vertex Pharmaceuticals INC / MA insiders were net sellers of VRTX, a net $11.0M across purchases and sales reported on Form 4 by 6 sellers. None of the 14 insider sales was flagged as made under a Rule 10b5-1 plan. In the year to 2026-10-27, 0 members of Congress disclosed buying VRTX and 1 member disclosed selling it; the latest on record is a sale by David J. Taylor dated 2026-08-26. Insiders filed 1 Form 144 notice of intent to sell in the 90 days to 2026-10-27, covering $662.5K of stock. Each figure is counted from SEC and House filings as of 2026-10-27, dated the day the filing was made public.

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies